123 related articles for article (PubMed ID: 2426218)
1. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay.
Ajani JA; Tomasovic B; Spitzer G; Kavanagh JJ; Thielvoldt D; Baker FL; Gershenson D
Invest New Drugs; 1986; 4(2):141-8. PubMed ID: 2426218
[TBL] [Abstract][Full Text] [Related]
2. Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.
Umbach GE; Hug V; Spitzer G; Thames H; Drewinko B
Invest New Drugs; 1984; 2(3):263-5. PubMed ID: 6210262
[TBL] [Abstract][Full Text] [Related]
3. Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Fuller AF; Krane IM; Budzik GP; Donahoe PK
Gynecol Oncol; 1985 Oct; 22(2):135-48. PubMed ID: 3932140
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.
Pierigè F; De Marco C; Orlotti N; Dominici S; Biagiotti S; Serafini S; Zaffaroni N; Magnani M; Rossi L
Int J Oncol; 2010 Jul; 37(1):133-42. PubMed ID: 20514405
[TBL] [Abstract][Full Text] [Related]
5. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial.
Garcia G; Smith CI; Weissberg JI; Eisenberg M; Bissett J; Nair PV; Mastre B; Rosno S; Roskamp D; Waterman K
Ann Intern Med; 1987 Sep; 107(3):278-85. PubMed ID: 2441633
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of fludarabine (2-fluoro-ara-AMP).
Kavanagh JJ; Krakoff IH; Bodey GP
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
[TBL] [Abstract][Full Text] [Related]
7. Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies.
Williams TJ; Lieber MM; Podratz KC; Malkasian GD
Am J Obstet Gynecol; 1983 Apr; 145(8):940-7. PubMed ID: 6837681
[TBL] [Abstract][Full Text] [Related]
8. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Boldt DH; Von Hoff DD; Kuhn JG; Hersh M
Cancer Res; 1984 Oct; 44(10):4661-6. PubMed ID: 6205751
[TBL] [Abstract][Full Text] [Related]
9. High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine.
McCann WP; Hall LM; Siler W; Barton N; Whitley RJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):265-73. PubMed ID: 2423028
[TBL] [Abstract][Full Text] [Related]
10. Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate.
Preiksaitis JK; Lank B; Ng PK; Brox L; LePage GA; Tyrrell DL
J Infect Dis; 1981 Oct; 144(4):358-64. PubMed ID: 6169773
[TBL] [Abstract][Full Text] [Related]
11. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD
Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer.
Mittelman A; Savona S; Puccio C; Chun H; Ahmed T; Feldman E; Sullivan P; Arnold P; Arlin Z
Invest New Drugs; 1990; 8 Suppl 1():S65-7. PubMed ID: 1696246
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B.
Perrillo RP; Regenstein FG; Bodicky CJ; Campbell CR; Sanders GE; Sunwoo YC
Gastroenterology; 1985 Mar; 88(3):780-6. PubMed ID: 2578421
[TBL] [Abstract][Full Text] [Related]
14. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
Danhauser L; Plunkett W; Keating M; Cabanillas F
Cancer Chemother Pharmacol; 1986; 18(2):145-52. PubMed ID: 2431803
[TBL] [Abstract][Full Text] [Related]
15. Effect of iontophoretic and topical application of antiviral agents in treatment of experimental HSV-1 keratitis in rabbits.
Kwon BS; Gangarosa LP; Park NH; Hull DS; Fineberg E; Wiggins C; Hill JM
Invest Ophthalmol Vis Sci; 1979 Sep; 18(9):984-8. PubMed ID: 90030
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of fludarabine in patients with epithelial ovarian cancer.
Kavanagh JJ; Stringer CA; Copeland LJ; Gershenson DM; Saul P
Cancer Treat Rep; 1986 Mar; 70(3):425-6. PubMed ID: 2420446
[No Abstract] [Full Text] [Related]
17. [Preliminary clinical experiences with adenine arabinoside monophosphate (ARA-AMP) in encephalitis due to viruses of the herpes group and varicella/zoster infections (author's transl)].
Sauer O; Werner GT; Schneider H; Lenard HG; von Haselberg L; Nettesheim HJ
Klin Padiatr; 1979 Nov; 191(6):566-71. PubMed ID: 92592
[TBL] [Abstract][Full Text] [Related]
18. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies.
Hill BT; Whelan RD; Gibby EM; Sheer D; Hosking LK; Shellard SA; Rupniak HT
Int J Cancer; 1987 Feb; 39(2):219-25. PubMed ID: 3804493
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of fludarabine phosphate (F-ara-AMP).
Casper ES; Mittelman A; Kelson D; Young CW
Cancer Chemother Pharmacol; 1985; 15(3):233-5. PubMed ID: 2414021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
